Get the latest Science News and Discoveries

Sacituzumab govitecan plus pembrolizumab does not meet primary endpoints in first-line PD-L1-high metastatic NSCLC

None

Related news:

In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC

Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC

Late-breaking HARMONi-2 analysis shows ivonescimab significantly improves overall survival versus pembrolizumab in PD-L1-Positive Advanced NSCLC

« Phase III ARTEMIS-008 trial shows risvutatug rezetecan significantly improves overall survival in relapsed small-cell lung cancer

Phase III MAVERICK trial supports brain MRI surveillance alone as standard of care for small-cell lung cancer »